FLUAD,FLUAD QUADRIVALENT Drug Profile

Summary for Tradename: FLUAD,FLUAD QUADRIVALENT

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLUAD,FLUAD QUADRIVALENT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLUAD,FLUAD QUADRIVALENT Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for FLUAD,FLUAD QUADRIVALENT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510			Patent claims search
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510		2030-10-28	Patent claims search

FLUAD,FLUAD QUADRIVALENT Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for FLUAD and FLUAD QUADRIVALENT

Introduction to FLUAD and FLUAD QUADRIVALENT

FLUAD and FLUAD QUADRIVALENT are adjuvanted influenza vaccines developed by Seqirus, a business unit of CSL Limited. These vaccines are designed to provide enhanced protection against seasonal influenza, particularly for high-risk populations such as adults 65 years and older.

Market Positioning

1. Recommendation by ACIP

   • The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has included FLUAD QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older[2]. This recommendation underscores the vaccine's safety and efficacy in this high-risk demographic.

2. Market Share

   • FLUAD QUADRIVALENT is part of Seqirus' differentiated portfolio of seasonal influenza vaccines. The company has reported strong growth in its adjuvanted products, including FLUAD, which contributed to a 16% increase in revenue at constant currency during the financial year 2024[3].

3. Global Reach

   • FLUAD has been distributed in over 30 countries and has more than 225 million doses distributed since its approval in 1997[2]. This extensive clinical legacy and global distribution network position FLUAD QUADRIVALENT as a leading influenza vaccine globally.

Market Segmentation

1. Quadrivalent Segment Dominance

   • The quadrivalent segment, which includes vaccines like FLUAD QUADRIVALENT, dominated the market in 2023 with a share of 86.77%[5]. This dominance is attributed to the high efficacy of quadrivalent vaccines against viral infections, their cost-effectiveness, and easy availability in clinics and hospitals.

2. Targeted Demographics

   • FLUAD QUADRIVALENT is specifically designed for adults 65 years and older. This demographic is particularly vulnerable to severe influenza-related complications, making targeted vaccination crucial for public health[2].

Financial Performance

1. Revenue Growth

   • CSL Seqirus reported solid growth in 2024, driven by strong performance in its adjuvanted products, including FLUAD[3]. The company's revenue from immunoglobulins grew by 20%, while adjuvanted products like FLUAD contributed to a 4% increase in revenue at constant currency.

2. Distribution Numbers

   • Seqirus distributed 110 million influenza vaccine doses in 2024, highlighting the significant volume of FLUAD and other influenza vaccines distributed globally[3].

3. Market Outlook

   • The global influenza vaccine market is projected to grow from $8.55 billion in 2024 to $17.77 billion by 2032, at a CAGR of 9.6%[1]. This growth is driven by increasing demand for influenza vaccines, especially in developing economies, and the expansion of vaccination coverage for high-risk populations.

Key Takeaways

1. Market Leadership

   • FLUAD QUADRIVALENT is a leading adjuvanted influenza vaccine recommended for high-risk populations, particularly adults 65 years and older.

2. Market Dominance

   • The quadrivalent segment, which includes FLUAD QUADRIVALENT, dominates the market due to its high efficacy, cost-effectiveness, and widespread availability.

3. Financial Performance

   • Seqirus has reported strong financial performance driven by the growth of its adjuvanted products, including FLUAD.

4. Global Reach

   • FLUAD has an extensive clinical legacy and has been distributed in over 30 countries, positioning it as a global leader in influenza vaccination.

FAQs

1. What is the primary recommendation for FLUAD QUADRIVALENT?

   • The U.S. CDC's ACIP recommends FLUAD QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older[2].

2. How does FLUAD QUADRIVALENT differ from other influenza vaccines?

   • FLUAD QUADRIVALENT is an adjuvanted vaccine designed to enhance the immune response, making it particularly effective for high-risk populations[2].

3. What is the market share of the quadrivalent segment in the influenza vaccine market?

   • The quadrivalent segment dominated the market with a share of 86.77% in 2023[5].

4. How has Seqirus performed financially in recent years?

   • Seqirus reported solid growth in 2024, driven by strong performance in its adjuvanted products, including FLUAD[3].

5. What is the projected growth rate of the global influenza vaccine market?

   • The global influenza vaccine market is projected to grow at a CAGR of 9.6% from 2024 to 2032[1].

Key Takeaways

• Market Leadership: FLUAD QUADRIVALENT is a leading adjuvanted influenza vaccine recommended for high-risk populations.
• Market Dominance: The quadrivalent segment, which includes FLUAD QUADRIVALENT, dominates the market due to its high efficacy and widespread availability.
• Financial Performance: Seqirus has reported strong financial performance driven by the growth of its adjuvanted products, including FLUAD.
• Global Reach: FLUAD has an extensive clinical legacy and has been distributed in over 30 countries, positioning it as a global leader in influenza vaccination.

Sources

1. Fortune Business Insights. (n.d.). Influenza Vaccine Market Size | Growth Analysis Report [2032]. Retrieved from https://www.fortunebusinessinsights.com/industry-reports/influenza-vaccine-market-101896
2. Seqirus. (n.d.). CDC Advisory Committee Includes FLUAD QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older. Retrieved from https://www.cslseqirus.us/news/fluad-quadrivalent-is-a-preferentially-recommended-influenza-vaccine-for-adults-65-and-older
3. CSL Limited. (2024). Annual Report for Financial Year 2024. Retrieved from https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf
4. GlobeNewswire. (2024, October 29). Demand For Innovative Therapies for Chronic Illnesses is set to Drive Growth in the Biologics Market is projected to reach USD 817.48 Billion by 2032 growing at a CAGR of 8.5% FMI. Retrieved from https://www.globenewswire.com/news-release/2024/10/29/2971037/0/en/Demand-For-Innovative-Therapies-for-Chronic-Illnesses-is-set-to-Drive-Growth-in-the-Biologics-Market-is-projected-to-reach-USD-817-48-Billion-by-2032-growing-at-a-CAGR-of-8-5-FMI.html
5. Grand View Research. (n.d.). Influenza Vaccine Market Size, Share & Growth Report, 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/influenza-vaccine-market-report